The role of complement system in septic shock

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Charchaflieh, Jean ^a,b   Wei, Jiandong ^a   Labaze, Georges ^a   Hou, Yunfang Joan ^a   Babarsh, Benjamin ^a   Stutz, Helen ^a   Lee, Haekyung ^a   Worah, Samrat ^a   Zhang, Ming ^a  

^a Downstate Health Sciences University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CORTICOSTEROID; CYTOKINE; ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN ASSOCIATED SERINE PROTEASE 2; NEUTRALIZING ANTIBODY; POLYMYXIN B; SERINE PROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COMPLEMENT;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG TARGETING; EXTRACORPOREAL IMMUNOADSORPTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOADSORPTION; INFLAMMATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESUSCITATION; SEPTIC SHOCK; SURVIVOR; TREATMENT OUTCOME; ANIMAL; COMPLEMENT LECTIN PATHWAY; IMMUNOLOGY; REVIEW;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; COMPLEMENT SYSTEM PROTEINS; HUMANS; SHOCK, SEPTIC;

EID: 84867366637     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/407324     Document Type: Article

References (90)

1. Rangel-Frausto M. S., Pittet D., Costigan M., Hwang T., Davis C. S., Wenzel R. P., The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. Journal of the American Medical Association 1995 273 2 117 123 2-s2.0-0028893025
2. Dombrovskiy V. Y., Martin A. A., Sunderram J., Paz H. L., Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Critical Care Medicine 2007 35 5 1244 1250 2-s2.0-34247338128 10.1097/01.CCM.0000261890.41311.E9 (Pubitemid 46642649)
3. Martin G. S., Mannino D. M., Eaton S., Moss M., The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine 2003 348 16 1546 1554 2-s2.0-0037451929 10.1056/NEJMoa022139 (Pubitemid 36437931)
4. De Kock I., Van Daele C., Poelaert J., Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy. Acta Clinica Belgica 2010 65 5 323 329 2-s2.0-78149366638
5. Robin M., Intrator L., Rapin M., Letter: complement activation in septic shock. The New England Journal of Medicine 1975 293 24 1261 1262 2-s2.0-0016849642
6. Graham D. I., Behan P. O., More I. A. R., Brain damage complicating septic shock. Acute haemorrhagic leucoencephalitis as a complication of the generalised Shwartzman reaction. Journal of Neurology Neurosurgery and Psychiatry 1979 42 1 19 28 2-s2.0-0018409511 (Pubitemid 9083196)
7. Fritz H., Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia): biochemical, pathophysiological and therapeutic aspects. Ciba Foundation Symposium 1979 75 351 379 2-s2.0-0018685752
8. Delsesto D., Opal S. M., Future perspectives on regulating pro-and anti-inflammatory responses in sepsis. Contributions to Microbiology 2011 17 137 156 2-s2.0-79959275431 10.1159/000324030
9. Hazelzet J. A., de Groot R., van Mierlo G., Joosten K. F. M., Van Der Voort E., Eerenberg A., Suur M. H., Hop W. C. J., Hack C. E., Complement activation in relation to capillary leakage in children with septic shock and purpura. Infection and Immunity 1998 66 11 5350 5356 2-s2.0-0032411277 (Pubitemid 29044630)
10. Groeneveld A. B. J., Tacx A. N., Bossink A. W. J., van Mierlo G. J., Hack C. E., Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clinical Immunology 2003 106 2 106 115 2-s2.0-0037301609 10.1016/S1521-6616(02)00025-6 (Pubitemid 36369405)
11. Groeneveld A. B. J., Hack C. E., The role of the innate immune response in hospital- versus community-acquired infection in febrile medical patients. International Journal of Infectious Diseases 2008 12 6 660 670 2-s2.0-54349092829 10.1016/j.ijid.2008.03.009
12. Hartemink K. J., Groeneveld A. B. J., The hemodynamics of human septic shock relate to circulating innate immunity factors. Immunological Investigations 2010 39 8 849 862 2-s2.0-77958160706 10.3109/08820139.2010.502949
13. Hack C. E., Nuijens J. H., Felt-Bersma R. J. F., Schreuder W. O., Eerenberg-Belmer A. J. M., Paardekooper J., Bronsveld W., Thijs L. G., Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with fatal outcome in sepsis. American Journal of Medicine 1989 86 1 20 26 2-s2.0-0024496137 (Pubitemid 19039532)
14. Dofferhoff A. S. M., de Jong H. J., Bom V. J., Van Der Meer J., Limburg P. C., De Vries-Hospers H. G., Marrink J., Mulder P. O. M., Weits J., Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. Scandinavian Journal of Infectious Diseases 1992 24 2 197 204 2-s2.0-0026696703
15. Furebring M., Håkansson L. D., Venge P., Nilsson B., Sjölin J., Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Critical Care 2002 6 4 363 370 2-s2.0-0036336515 10.1186/cc1524 (Pubitemid 34863706)
16. Shatney C. H., Benner C., Sequential serum complement (C3) and immunoglobulin levels in shock/trauma patients developing acute fulminant systemic sepsis. Circulatory Shock 1985 16 1 9 17 2-s2.0-0021845395 (Pubitemid 15062798)
17. Bergh K., Olsen P. O., Halgunset J., Iversen O. J., Complement activation and pulmonary dysfunction in experimental Escherichia coli septicaemia. Acta Anaesthesiologica Scandinavica 1991 35 3 267 274 2-s2.0-0025969457
18. Mollnes T. E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O., Schlag G., Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clinical and Experimental Immunology 1993 91 2 295 300 2-s2.0-0027531731 (Pubitemid 23045677)
19. Schuerholz T., Leuwer M., Cobas-Meyer M., Vangerow B., Kube F., Kirschfink M., Marx G., Terminal complement complex in septic shock with capillary leakage: marker of complement activation? European Journal of Anaesthesiology 2005 22 7 541 547 2-s2.0-22244443693 10.1017/S0265021505000931 (Pubitemid 40992759)
20. Chen N. J., Mirtsos C., Suh D., Lu Y. C., Lin W. J., McKerlie C., Lee T., Baribault H., Tian H., Yeh W. C., C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007 446 7132 203 207 2-s2.0-33947110020 10.1038/nature05559 (Pubitemid 46398661)
21. Rittirsch D., Flierl M. A., Nadeau B. A., Day D. E., Huber-Lang M., Mackay C. R., Zetoune F. S., Gerard N. P., Cianflone K., Köhl J., Gerard C., Sarma J. V., Ward P. A., Functional roles for C5a receptors in sepsis. Nature Medicine 2008 14 5 551 557 2-s2.0-43249098418 10.1038/nm1753 (Pubitemid 351655216)
22. Flierl M. A., Rittirsch D., Chen A. J., Nadeau B. A., Day D. E., Sarma J. V., Huber-Lang M. S., Ward P. A., The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS ONE 2008 3 7 2-s2.0-50149117225 10.1371/journal.pone.0002560 e2560
23. Fischer M. B., Prodeus A. P., Nicholson-Weller A., Ma M., Murrow J., Reid R. R., Warren H. B., Lage A. L., Moore F. D., Rosen F. S., Carroll M. C., Increased susceptibility to endotoxin shock in complement C3- and C4- deficient mice is corrected by C1 inhibitor replacement. Journal of Immunology 1997 159 2 976 982 2-s2.0-0031570885 (Pubitemid 127484253)
24. Flierl M. A., Rittirsch D., Nadeau B. A., Day D. E., Zetoune F. S., Sarma J. V., Huber-Lang M. S., Ward P. A., Functions of the complement components C3 and C5 during sepsis. The FASEB Journal 2008 22 10 3483 3490 2-s2.0-54049102451 10.1096/fj.08-110595
25. Brauer R. B., Gegenfurtner C., Neumann B., Stadler M., Heidecke C. D., Holzmann B., Endotoxin-induced lung inflammation is independent of the complement membrane attack complex. Infection and Immunity 2000 68 3 1626 1632 2-s2.0-0033982990 10.1128/IAI.68.3.1626-1632.2000 (Pubitemid 30108566)
26. Reid R. R., Prodeus A. P., Khan W., Hsu T., Rosen F. S., Carroll M. C., Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. Journal of Immunology 1997 159 2 970 975 2-s2.0-0031570884 (Pubitemid 127484252)
27. León C., Rodrigo M. J., Tomasa A., Gallart M. T., Latorre F. J., Rius J., Brugués J., Complement activation in septic shock due to gram-negative and gram-positive bacteria. Critical Care Medicine 1982 10 5 308 310 2-s2.0-0020130716
28. Sprung C. L., Schultz D. R., Marcial E., Complement activation in septic shock patients. Critical Care Medicine 1986 14 6 525 528 2-s2.0-0022477320 (Pubitemid 16085528)
29. Lin R. Y., Astiz M. E., Saxon J. C., Saha D. C., Rackow E. C., Alterations in C3, C4, factor B, and related metabolites in septic shock. Clinical Immunology and Immunopathology 1993 69 2 136 142 2-s2.0-0027501089 10.1006/clin.1993.1161 (Pubitemid 23319379)
30. Andaluz-Ojeda D., Iglesias V., Bobillo F., Almansa R., Rico L., Gandia F., Loma A. M., Nieto C., Diego R., Ramos E., Nocito M., Resino S., Eiros J. M., Tamayo E., de Lejarazu R. O., Bermejo-Martin J. F., Early natural killer cell counts in blood predict mortality in severe sepsis. Critical Care 2011 15, article R243
31. Derkx H. H. F., Kuijper E. J., Fijen C. A. P., Jak M., Dankert J., Van Deventer S. J. H., Inherited complement deficiency in children surviving fulminant meningococcal septic shock. European Journal of Pediatrics 1995 154 9 735 738 2-s2.0-0029081348
32. Sprong T., Roos D., Weemaes C., Neeleman C., Geesing C. L. M., Mollnes T. E., Van Deuren M., Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006 107 12 4865 4870 2-s2.0-33745095332 10.1182/blood-2005-07-2820 (Pubitemid 43882639)
33. Genel F., Atlihan F., Gulez N., Sjöholm A. G., Skattum L., Truedsson L., Properdin deficiency in a boy with fulminant meningococcal septic shock. Acta Paediatrica 2006 95 11 1498 1500 2-s2.0-33750408201 10.1080/ 08035250600603008 (Pubitemid 44643569)
34. Oglesby T. J., Schultz D. R., Schein R. M. H., Sprung C. L., Volanakis J. E., Measurement of complement proteins C2 and B in systemic lupus erythematosus and septic shock. Complement and Inflammation 1989 6 1 27 35 2-s2.0-0024574826 (Pubitemid 19035447)
35. Brandtzaeg P., Hogåsen K., Kierulf P., Mollnes T. E., The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. Journal of Infectious Diseases 1996 173 3 647 655 2-s2.0-0030041379 (Pubitemid 26064066)
36. Goring K., Huang Y., Mowat C., Léger C., Lim T. H., Zaheer R., Mok D., Tibbles L. A., Zygun D., Winston B. W., Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C. American Journal of Physiology 2009 296 5 C1140 C1150 2-s2.0-66149084764 10.1152/ajpcell.00071.2009
37. Matsushita M., Fujita T., Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. Journal of Experimental Medicine 1992 176 6 1497 1502 2-s2.0-0026445745 10.1084/jem.176.6.1497
38. Schwaeble W., Dahl M. R., Thiel S., Stover C., Jensenius J. C., The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology 2002 205 4-5 455 466 2-s2.0-0036748253 (Pubitemid 35153961)
39. Roos A., Bouwman L. H., Munoz J., Zuiverloon T., Faber-Krol M. C., Fallaux-van den Houten F. C., Klar-Mohamad N., Hack C. E., Tilanus M. G., Daha M. R., Functional characterization of the lectin pathway of complement in human serum. Molecular Immunology 2003 39 11 655 668 2-s2.0-18744371008 10.1016/S0161-5890(02)00254-7 (Pubitemid 35454078)
40. Turner M. W., The role of mannose-binding lectin in health and disease. Molecular Immunology 2003 40 7 423 429 2-s2.0-0141918816 10.1016/S0161-5890(03) 00155-X (Pubitemid 37244035)
41. Tsutsumi A., Takahashi R., Sumida T., Mannose binding lectin: genetics and autoimmune disease. Autoimmunity Reviews 2005 4 6 364 372 2-s2.0-23144460728 10.1016/j.autrev.2005.02.004 (Pubitemid 41080073)
42. Petersen S. V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., Jensenius J. C., Control of the classical and the MBL pathway of complement activation. Molecular Immunology 2001 37 14 803 811 2-s2.0-0035099159 10.1016/S0161-5890(01) 00004-9 (Pubitemid 32226376)
43. Presanis J. S., Hajela K., Ambrus G., Gál P., Sim R. B., Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Molecular Immunology 2004 40 13 921 929 2-s2.0-0347915527 10.1016/j.molimm.2003. 10.013 (Pubitemid 38077036)
44. Kerr F. K., Thomas A. R., Wijeyewickrema L. C., Whisstock J. C., Boyd S. E., Kaiserman D., Matthews A. Y., Bird P. I., Thielens N. M., Rossi V., Pike R. N., Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Molecular Immunology 2008 45 3 670 677 2-s2.0-34848895085 10.1016/j.molimm.2007.07.008 (Pubitemid 47498592)
45. Zhao L., Ohtaki Y., Yamaguchi K., Matsushita M., Fujita T., Yokochi T., Takada H., Endo Y., LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood 2002 100 9 3233 3239 2-s2.0-0036838524 10.1182/blood-2002-01-0252 (Pubitemid 35217072)
46. Dean M. M., Minchinton R. M., Heatley S., Eisen D. P., Mannose binding lectin acute phase activity in patients with severe infection. Journal of Clinical Immunology 2005 25 4 346 352 2-s2.0-23944476362 10.1007/s10875-005- 4702-1 (Pubitemid 41204259)
47. Eisen D. P., Dean M. M., Thomas P., Marshall P., Gerns N., Heatley S., Quinn J., Minchinton R. M., Lipman J., Low mannose-binding lectin function is associated with sepsis in adult patients. FEMS Immunology and Medical Microbiology 2006 48 2 274 282 2-s2.0-33750084149 10.1111/j.1574-695X.2006. 00144.x (Pubitemid 44581592)
48. Sprong T., Mollnes T. E., Neeleman C., Swinkels D., Netea M. G., Van Der Meer J. W. M., Van Deuren M., Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clinical Infectious Diseases 2009 49 9 1380 1386 2-s2.0-72849142469 10.1086/606054
49. Cinel I., Opal S. M., Molecular biology of inflammation and sepsis: a primer. Critical Care Medicine 2009 37 1 291 304 2-s2.0-59649117667 10.1097/CCM.0b013e31819267fb
50. Jean-Baptiste E., Cellular mechanisms in sepsis. Journal of Intensive Care Medicine 2007 22 2 63 72 2-s2.0-34047258169 10.1177/0885066606297123 (Pubitemid 46548124)
51. Zanotti-Cavazzonia S. L., Hollenberg S. M., Cardiac dysfunction in severe sepsis and septic shock. Current Opinion in Critical Care 2009 15 5 392 397 2-s2.0-70350123038 10.1097/MCC.0b013e3283307a4e
52. Levy B., Collin S., Sennoun N., Ducrocq N., Kimmoun A., Asfar P., Perez P., Meziani F., Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Medicine 2010 36 12 2019 2029 2-s2.0-78649316272 10.1007/s00134-010-2045-8
53. Fourrier F., Jourdain M., Tournois A., Caron C., Goudemand J., Chopin C., Coagulation inhibitor substitution during sepsis. Intensive Care Medicine 1995 21 supplement 2 S264 S268 2-s2.0-19244373960 10.1007/BF01740765
54. Davis A. E. 3rd, Structure and function of C1 inhibitor. Behring Institut Mitteilungen 1989 84 142 150 2-s2.0-0024376469
55. Matsushita M., Thiel S., Jensenius J. C., Terai I., Fujita T., Proteolytic activities of two types of mannose-binding lectin-associated serine protease. Journal of Immunology 2000 165 5 2637 2642 2-s2.0-0034284459 (Pubitemid 30660711)
56. Jiang H., Wagner E., Zhang H., Frank M. M., Complement 1 inhibitor is a regulator of the alternative complement pathway. Journal of Experimental Medicine 2001 194 11 1609 1616 2-s2.0-0035803369 10.1084/jem.194.11.1609 (Pubitemid 33126811)
57. Wuillemin W. A., Fijnvandraat K., Derkx B. H. F., Peters M., Vreede W., Ten Cate H., Hack C. E., Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thrombosis and Haemostasis 1995 74 6 1436 1441 2-s2.0-0029562092 (Pubitemid 26018069)
58. Gullo A., Foti A., Murabito P., Li Volti G., Astuto M., Stissi C., Rubulotta F., Sanfilippo F., Santonocito C., Sganga G., Ristagno G., Spectrum of sepsis, mediators, source control and management of bundles. Frontiers in Bioscience 2010 2 906 911 2-s2.0-77957350925
59. de Boer J. P., Wolbink G. J., Thijs L. G., Baars J. W., Wagstaff J., Hack C. E., Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 1992 24 2 135 148 2-s2.0-0026592196 10.1016/0162-3109(92)90019-9
60. Hack C. E., De Groot E. R., Felt-Bersma R. J. F., Nuijens J. H., Strack Van Schijndel R. J. M., Eerenberg-Belmer A. J. M., Thijs L. G., Aarden L. A., Increased plasma levels of interleukin-6 in sepsis. Blood 1989 74 5 1704 1710 2-s2.0-0024451525 (Pubitemid 19251549)
61. Brandtzaeg P., Osnes L., Ovstebo R., Joo G. B., Westvik A. B., Kierulf P., Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. Journal of Experimental Medicine 1996 184 1 51 60 2-s2.0-0030036614 10.1084/jem.184.1.51 (Pubitemid 26247214)
62. Bossink A. W. J., Paemen L., Jansen P. M., Hack C. E., Thijs L. G., Van Damme J., Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood 1995 86 10 3841 3847 2-s2.0-0028788487
63. Wakabayashi G., Gelfand J. A., Jung W. K., Connolly R. J., Burke J. F., Dinarello C. A., Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia: comparison to Escherichia coli. Journal of Clinical Investigation 1991 87 6 1925 1935 2-s2.0-0026093615
64. Slotman G. J., Burchard K. W., Williams J. J., Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension. Surgery 1986 99 6 744 751 2-s2.0-0022515408 (Pubitemid 16069119)
65. Gijon M. A., Perez C., Mendez E., Sanchez Crespo M., Phospholipase A2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin: some implications for its functional role. Biochemical Journal 1995 306 167 175 2-s2.0-0028985053
66. Funk D., Sebat F., Kumar A., A systems approach to the early recognition and rapid administration of best practice therapy in sepsis and septic shock. Current Opinion in Critical Care 2009 15 4 301 307 2-s2.0-68949178454 10.1097/MCC.0b013e32832e3825
67. Textoris J., Wiramus S., Martin C., Leone M., Antibiotic therapy in patients with septic shock. European Journal of Anaesthesiology 2011 28 5 318 324 2-s2.0-79959825740 10.1097/EJA.0b013e328346c0de
68. Davies B., Cohen J., Endotoxin removal devices for the treatment of sepsis and septic shock. The Lancet Infectious Diseases 2011 11 1 65 71 2-s2.0-78650233801 10.1016/S1473-3099(10)70220-6
69. Ramos F. J. D., Azevedo L. C., Hemodynamic and perfusion end points for volemic resuscitation in sepsis. Shock 2010 34 supplement 1 34 39 10.1097/SHK.0b013e3181e7e642
70. Rivers E. P., Jaehne A. K., Eichhorn-Wharry L., Brown S., Amponsah D., Fluid therapy in septic shock. Current Opinion in Critical Care 2010 16 4 297 308 10.1097/MCC.0b013e32833be8b3
71. Annane D., Bellissant E., Bollaert P. E., Briegel J., Confalonieri M., De Gaudio R., Keh D., Kupfer Y., Oppert M., Meduri G. U., Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. Journal of the American Medical Association 2009 301 22 2362 2375 2-s2.0-67049108021 10.1001/jama.2009.815
72. Vincent J. L., Carrasco Serrano E., Dimoula A., Current management of sepsis in critically ill adult patients. Expert Review of Anti-Infective Therapy 2011 9 7 847 856 2-s2.0-79961181513 10.1586/eri.11.65
73. Ramakers B. P., Riksen N. P., van der Hoeven J. G., Smits P., Pickkers P., Modulation of innate immunity by adenosine receptor stimulation. Shock 2011 36 208 215 2-s2.0-79957532595 10.1097/SHK.0b013e318225aee4
74. Hangen D. H., Stevens J. H., Satoh P. S., Hall E. W., O'Hanley P. T., Raffin T. A., Complement levels in septic primates treated with anti-C5a antibodies. Journal of Surgical Research 1989 46 3 195 199 2-s2.0-0024598582 (Pubitemid 19098325)
75. Smedegard G., Cui L., Hugli T. E., Endotoxin-induced shock in the rat. A role for C5a. American Journal of Pathology 1989 135 3 489 497 2-s2.0-0024450510 (Pubitemid 19246207)
76. Höpken U., Mohr M., Strüber A., Montz H., Burchardi H., Götze O., Oppermann M., Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. European Journal of Immunology 1996 26 5 1103 1109 2-s2.0-0029980816 10.1002/eji.1830260522 (Pubitemid 26158509)
77. Ward P. A., Guo R. F., Riedemann N. C., Manipulation of the complement system for benefit in sepsis. Critical Care Research and Practice 2012 2012 427607
78. Alves-Filho J. C., Spiller F., Cunha F. Q., Neutrophil paralysis in sepsis. Shock 2010 34 supplement 1 15 21 2-s2.0-77955985078 10.1097/SHK. 0b013e3181e7e61b
79. Reddy R. C., Standiford T. J., Effects of sepsis on neutrophil chemotaxis. Current Opinion in Hematology 2010 17 1 18 24 2-s2.0-73849117987 10.1097/MOH.0b013e32833338f3
80. Jansen P. M., Eisele B., de Jong I. W., Chang A., Delvos U., Taylor F. B., Hack C. E., Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. Journal of Immunology 1998 160 1 475 484 2-s2.0-0031883545 (Pubitemid 28116764)
81. Zhang H., Li J., Barrington R. A., Liang G., Qin G., Liu D. X., An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor. Biochemical and Biophysical Research Communications 2007 359 2 285 291 2-s2.0-34249943568 10.1016/j.bbrc.2007.05.078 (Pubitemid 46880503)
82. Fronhoffs S., Luyken J., Steuer K., Hansis M., Vetter H., Walger P., The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Medicine 2000 26 10 1566 1570 2-s2.0-0033791945 10.1007/s001340000654
83. Zeerleder S., Caliezi C., van Mierlo G., Eerenberg-Belmer A., Sulzer I., Hack C. E., Wuillemin W. A., Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clinical and Diagnostic Laboratory Immunology 2003 10 4 529 535 2-s2.0-0038445541 10.1128/CDLI.10.4.529-535.2003 (Pubitemid 36890433)
84. Qiu P., Cui X., Barochia A., Li Y., Natanson C., Eichacker P. Q., The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opinion on Investigational Drugs 2011 20 1555 1564 10.1517/13543784.2011.623125
85. Bengtsson A., Redl H., Schlag G., Högåsen K., Götze O., Mollnes T. E., Anti-TNF treatment of baboons with sepsis reduces TNF- α IL-16 and IL- 8, but not the degree of complement activation. Scandinavian Journal of Immunology 1998 48 5 509 514 2-s2.0-0031761019 10.1046/j.1365-3083. 1998.00433.x (Pubitemid 28505676)
86. Sato T., Orlowski J. P., Zborowski M., Experimental study of extracorporeal perfusion for septic shock. American Society for Artificial Internal Organs Journal 1993 39 3 M790 M793 2-s2.0-0027385965 10.1097/00002480-199307000-00130 (Pubitemid 23311808)
87. Stegmayr B. G., Plasmapheresis in severe sepsis or septic shock. Blood Purification 1996 14 1 94 101 2-s2.0-0030052232 (Pubitemid 26034611)
88. Mitaka C., Tomita M., Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock. Shock 2011 36 332 338 2-s2.0-79958065638 10.1097/SHK.0b013e318225f839
89. Reeves J. H., Butt W. W., Shann F., Layton J. E., Stewart A., Waring P. M., Presneill J. J., Santamana J. D., Hart G. K., Corke C., Scheinkestel C., Cranswick P. J., Lhle B., Continuous plasmafiltration in sepsis syndrome. Critical Care Medicine 1999 27 10 2096 2104 2-s2.0-0032706914 10.1097/00003246-199910000-00003 (Pubitemid 29508319)
90. Schefold J. C., von Haehling S., Corsepius M., Pohle C., Kruschke P., Zuckermann H., Volk H. D., Reinke P., A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 2007 28 4 418 425 2-s2.0-33947399112 10.1097/shk.0b013e31804f5921 (Pubitemid 47415252)